ArticleSubstance use & misuse2023
Scope of, Motivations for, and Outcomes Associated with Buprenorphine Diversion in the United States: A Scoping Review.
Article in Substance use & misuse, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 21 citations in OpenAlex.
- Concurrent Use of Extra-Medical Medication for Opioid Use Disorder Among Adults Prescribed Methadone or Buprenorphine: A Cohort Study of Urban Adults Who Have Injected Drugs.Drug and alcohol review · 2026Article
- Acceptability and Appropriateness of Harm Reduction Vending Machines Compared to Syringe Service Programs in Appalachian Kentucky.Journal of studies on alcohol and drugs · 2026Article
- Low-threshold Buprenorphine: Proposing the Ideal Service Model to Engage People With Severe Opioid Use Disorder.Journal of addiction medicine · 2026Article
- Who Should Respond to Substance-Exposed Infants? Reflections on U.S. Policies Limiting the Role of Child Protective Services.Child protection and practice · 2025Article
- State-Mandated Opioid Use Disorder Treatment In Maryland Jails Helped Patients Recover Despite Gaps In Care.Health affairs (Project Hope) · 2025Article
- Factors contributing to the expansion of medication for opioid use disorder (MOUD) within the New Hampshire Department of Corrections (NHDOC).Health & justice · 2025Article
- Real-world access to buprenorphine treatment in Philadelphia: A secret shopper study.Drug and alcohol dependence · 2025Article
- Perspectives of substance use disorder counselors on the benefits and drawbacks of medications for opioid use disorder.Addiction science & clinical practice · 2025Article
- State Medicaid Policies Governing Access to Medications for Opioid Use Disorder (MOUD) and MOUD Treatment Use in a Large Sample of People Who Inject Drugs in 20 U.S. States.Substance use & misuse · 2025Article
- Concerns About Medications for Opioid Use Disorder Among American Indian Community Members: A Qualitative Secondary Analysis.Public opinion quarterly · 2025Article
- Perspectives of substance use disorder counselors on the benefits and drawbacks of medications for opioid use disorder.Research square · 2024Article
- Sources of nonmedically used prescription psychotherapeutic drugs using real-world data from adolescents and adults assessed for substance use treatment--2014-2022.Research in social & administrative pharmacy : RSAP · 2024Article
- Assessing suboxone access in community pharmacies: Secret shopper model.Exploratory research in clinical and social pharmacy · 2023Article
- Diversion of medications to treat opioid use disorder: Qualitative findings from formerly incarcerated adults in Massachusetts.The International journal on drug policy · 2023Article
- Stigma towards opioid use disorder in primary care remain a barrier to integrating software-based measurement based care.BMC psychiatry · 2023Article
- Examining buprenorphine diversion through a harm reduction lens: an agent-based modeling study.Harm reduction journal · 2023Article
- Identifying Barriers to OUD Treatment Linkage From the Emergency Department to the Community.JAMA network open · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
backgroundExpanding access to medications to treat opioid use disorder (OUD), such as buprenorphine, is an evidence-based response to the mounting drug overdose crisis. However, concerns about buprenorphine diversion persist and contribute to limited access.
methodsTo inform decisions about expanding access, a scoping review was conducted on publications describing the scope of, motivations for, and outcomes associated with diverted buprenorphine in the U.S.
resultsIn the 57 included studies, definitions for diversion were inconsistent. Most studied use of illicitly-obtained buprenorphine. Across studies, the scope of buprenorphine diversion ranged from 0% to 100%, varying by sample type and recall period. Among samples of people receiving buprenorphine for OUD treatment, diversion peaked at 4.8%. Motivations for using diverted buprenorphine were self-treatment, management of drug use, to get high, and when drug of choice was unavailable. Associated outcomes examined trended toward positive or neutral, including improved attitudes toward and retention in MOUD.
conclusionsDespite inconsistent definitions of diversion, studies reported a low scope of diversion among people receiving MOUD, with inability to access treatment as a motivating factor for
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.